Literature DB >> 26402369

Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristics.

Gabriele Todisco1, Taghi Manshouri1, Srdan Verstovsek1, Lucia Masarova1, Sherry A Pierce1, Michael J Keating1, Zeev Estrov1.   

Abstract

Chronic lymphocytic leukemia (CLL) and myeloproliferative neoplasms (MPN) may occur concomitantly. However, little is known about the pathobiological characteristics and interaction between the neoplastic clones in these rare cases of coinciding malignancies. We retrospectively examined the clinical and biological characteristics of 13 patients with concomitant CLL and MPN--eight primary myelofibrosis (PMF), three essential thrombocytosis (ET), and two polycythemia vera (PV)--who presented to our institution between 1998 and 2014, and tested all patients for MPN-specific aberrations, such as JAK2, MPL and CALR mutations. Along with epidemiological and molecular characterization of this rare condition, we found that JAK2 mutation can be detected 9 years prior to PMF diagnosis, suggesting that PMF clinical phenotype may require several years to develop and CLL/MPN clinical co-occurrence might be sustained by common molecular events. Some features of these patients suggest that pathobiologies of these diseases might be intertwined.

Entities:  

Keywords:  CALR; Chronic lymphocytic leukemia; JAK2; MPL; myeloproliferative neoplasms; primary myelofibrosis

Mesh:

Substances:

Year:  2015        PMID: 26402369      PMCID: PMC4837105          DOI: 10.3109/10428194.2015.1092527

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  39 in total

1.  Maximum-likelihood estimation of demographic parameters using the frequency spectrum of unlinked single-nucleotide polymorphisms.

Authors:  Alison M Adams; Richard R Hudson
Journal:  Genetics       Date:  2004-11       Impact factor: 4.562

2.  Hematopoietic stem cells: the paradigmatic tissue-specific stem cell.

Authors:  David Bryder; Derrick J Rossi; Irving L Weissman
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

3.  Polycythemia vera is not initiated by JAK2V617F mutation.

Authors:  Roberto H Nussenzveig; Sabina I Swierczek; Jaroslav Jelinek; Amos Gaikwad; Enli Liu; Srdan Verstovsek; Jaroslav F Prchal; Josef T Prchal
Journal:  Exp Hematol       Date:  2007-01       Impact factor: 3.084

4.  Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation.

Authors:  Luciana Teofili; Maurizio Martini; Tonia Cenci; Giovanna Petrucci; Lorenza Torti; Sergio Storti; Francesco Guidi; Giuseppe Leone; Luigi Maria Larocca
Journal:  Blood       Date:  2007-03-21       Impact factor: 22.113

5.  Incidence of chronic lymphocytic leukemia in Olmsted County, Minnesota, 1935 through 1989, with emphasis on changes in initial stage at diagnosis.

Authors:  T G Call; R L Phyliky; P Noël; T M Habermann; C M Beard; W M O'Fallon; L T Kurland
Journal:  Mayo Clin Proc       Date:  1994-04       Impact factor: 7.616

Review 6.  Myelofibrosis with myeloid metaplasia.

Authors:  A Tefferi
Journal:  N Engl J Med       Date:  2000-04-27       Impact factor: 91.245

7.  Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis.

Authors:  F Cervantes; J C Hernández-Boluda; N Villamor; A Serra; E Montserrat
Journal:  Eur J Haematol       Date:  2000-08       Impact factor: 2.997

8.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

9.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

10.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

View more
  7 in total

Review 1.  Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.

Authors:  Naveen Pemmaraju; Hagop Kantarjian; Loretta Nastoupil; Megan Dupuis; Lisa Zhou; Sherry Pierce; Keyur P Patel; Lucia Masarova; Jorge Cortes; Srdan Verstovsek
Journal:  Blood       Date:  2019-02-22       Impact factor: 22.113

2.  Concomitant Diagnosis of Primary Bone Marrow B-Cell Non-Hodgkin Lymphoma and Essential Thrombocythemia: A Case Report.

Authors:  Hongkyung Kim; Hye Min Kim; Jin Ju Kim; Saeam Shin; Doh Yu Hwang; Seung-Tae Lee; Jong Rak Choi
Journal:  Ann Lab Med       Date:  2022-03-01       Impact factor: 3.464

3.  Rapid Emergence of Chronic Lymphocytic Leukemia During JAK2 Inhibitor Therapy in a Patient With Myelofibrosis.

Authors:  Nikolaos Sousos; Gemma Buck; Alba Rodriguez-Meira; Ruggiero Norfo; Angela Hamblin; Francesco Pezzella; Jennifer Davies; Philip Hublitz; Bethan Psaila; Adam J Mead
Journal:  Hemasphere       Date:  2020-05-27

4.  Chronic Lymphocytic Leukemia and Myelofibrosis.

Authors:  Fares Darawshy; Arieh Ben-Yehuda; Karine Atlan; Deborah Rund
Journal:  Case Rep Hematol       Date:  2018-08-08

5.  Concomitant Essential Thrombocythemia and Mature B -Lymphoproliferative Disorder in a Patient.

Authors:  Ayesha Butt; Ruhul Quddus; Natasha Ali
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2021-10-01

6.  Lymphoproliferative and Subsequent Myeloproliferative Disorder - A One Way Street?

Authors:  Pawina Subedi; Yugandhara Kate; Masood Pasha Syed; A Daniyal Siddiqui
Journal:  Balkan Med J       Date:  2021-05       Impact factor: 2.021

7.  Primary Myelofibrosis Occurring during Targeted Therapy for Chronic Lymphocytic Leukemia: A Report of Two Cases.

Authors:  Francesco Angotzi; Andrea Visentin; Federico Scarmozzino; Alessandro Cellini; Roberta Bertorelle; Marco Pizzi; Gianni Binotto; Angelo Paolo Dei Tos; Livio Trentin
Journal:  Curr Oncol       Date:  2022-02-27       Impact factor: 3.677

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.